Dementia is a common condition in older people, with at least 7% of people over 65 years old in the UK affected, and numbers are increasing worldwide. In this review, we wanted to discover whether ...

Objectives To assess the cost-effectiveness of aducanumab at its updated price for treating patients with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD). Design Cost-effectiveness ...

Not all memory loss is degenerative or permanent. Here's what medical experts say to do if you're experiencing symptoms.

A membrane transport protein called SLC13A5 has previously been linked to a severe form of epileptic encephalopathy.

To reduce the societal incidence of dementia, it is essential to detect MCI early in medical settings and to implement community-based screening among older adults. The Montreal Cognitive Assessment ...

Objectives: This research aims to validate a modified visually based Montreal Cognitive Assessment for hearing-aid users (MoCA-HA). This population should be the target of cognitive screening due to ...

Memantine, the only drug approved for the treatment of Alzheimer's disease, has recently been made available in an extended-release formulation. What do you need to know about this new product?

Memantine's beneficial effect on time to institutionalization and total societal costs for moderate-to-severe Alzheimer's patients was further supported by two cost-effective analyses performed in ...

Where you live in the U.S. may influence dementia risk, with a growing body of evidence showing regional differences in rates among older veterans.